Quantitative immunoassay for IgA class circulating immune complexes using solid phase Facb fragment of anti-C3.

Area of Science:

• Immunology
• Clinical Chemistry
• Assay Development

Background:

• Circulating immune complexes (CIC) are implicated in autoimmune diseases.
• Quantifying IgA class CIC (IgA-CIC) is crucial for understanding disease pathogenesis.
• Existing assays may suffer from inaccuracies due to interfering antibodies.

Purpose of the Study:

• To develop and validate a quantitative assay for IgA-CIC.
• To address limitations of previous methods, specifically false positives.
• To establish a reliable method for clinical use.

Main Methods:

• Development of a stable IgA-CIC standard by chemically binding complement C3 to human serum IgA.
• Utilizing a solid phase Fc fragment of anti-C3 (Facb anti-C3) in an enzyme immunoassay (EIA).
• Testing sera from patients with systemic lupus erythematosus (SLE) to evaluate assay performance.

Main Results:

• A stable and reproducible IgA-CIC standard was successfully prepared.
• The Facb anti-C3 EIA eliminated false positive results caused by IgA class anti-F(ab')2 antibodies and IgA class rheumatoid factor.
• The assay demonstrated good reproducibility and recovery, validated by the IgA-C3 standard.

Conclusions:

• The developed Facb anti-C3 EIA provides a robust and accurate method for quantifying IgA-CIC.
• This assay overcomes common interference issues, enhancing diagnostic utility.
• The method holds promise for clinical applications in studying the role of IgA-CIC in various diseases.